In this episode of Med Tech Talks, Robert Klupacs is joined by Dr Megan Baldwin, Founder, Chief Innovation Officer and Executive Director of Opthea Limited.

Opthea limited is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases. They have a world class team of ophthalmology experts working to develop breakthrough therapies for those who suffer from retinal disease.

Megan has over 20 years of experience focusing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. With a PhD in medicine from the University of Melbourne, and having conducted her postdoctoral studies at Genentech, Megan joined Circadian Technologies Limited, now Opthea, in 2008 as Head of Preclinical R&D, and became Chief Executive in 2014. Today, she's a member of the Australian Institute for Company Directors, a board member of AusBiotech and serves on the boards of public and private companies.

In this episode you will hear about:

How Opthea is working to improve outcomes for patients with wet AMD.
Insight into Opthea’s strategy for attracting investment in its early-stage research and beyond
What Megan thinks Australia needs to do in order to support translation of Australian innovation
Megan’s advice for seeking mentorship and the importance of looking outside of your network.

Learn more about Opthea.

Read about Megan Baldwin.

Updated version 05/08/22

Brexit vote cancelled: what happened?